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Abstract
Background: Multiplex ligation-dependent probe amplification (MLPA) is a powerful tool to identify genomic
polymorphisms. We have previously developed a single nucleotide polymorphism (SNP) and large sequence
polymorphisms (LSP)-based MLPA assay using a read out on a liquid bead array to screen for 47 genetic markers in
the Mycobacterium tuberculosis genome. In our assay we obtain information regarding the Mycobacterium
tuberculosis lineage and drug resistance simultaneously. Previously we called the presence or absence of a
genotypic marker based on a threshold signal level. Here we present a more elaborate data analysis method to
standardize and streamline the interpretation of data generated by MLPA. The new data analysis method also
identifies intermediate signals in addition to classification of signals as positive and negative. Intermediate calls can
be informative with respect to identifying the simultaneous presence of sensitive and resistant alleles or infection
with multiple different Mycobacterium tuberculosis strains.
Results: To validate our analysis method 100 DNA isolates of Mycobacterium tuberculosis extracted from cultured
patient material collected at the National TB Reference Laboratory of the National Center for Tuberculosis and Lung
Diseases in Tbilisi, Republic of Georgia were tested by MLPA. The data generated were interpreted blindly and then
compared to results obtained by reference methods. MLPA profiles containing intermediate calls are flagged for
expert review whereas the majority of profiles, not containing intermediate calls, were called automatically. No
intermediate signals were identified in 74/100 isolates and in the remaining 26 isolates at least one genetic marker
produced an intermediate signal.
Conclusion: Based on excellent agreement with the reference methods we conclude that the new data analysis
method performed well. The streamlined data processing and standardized data interpretation allows the
comparison of the Mycobacterium tuberculosis MLPA results between different experiments. All together this will
facilitate the implementation of the MLPA assay in different settings.
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Background
Bacterial genotyping has a recognized potential to sup-
port tuberculosis (TB) control [1]. After initial diagnosis
and before administered standardized empirical therapy
timely detection of resistance mutations in the genome
of Mycobacterium tuberculosis (MTB) can help clinical
decision-making and support infection control efforts.
Further, combined resistance and lineage identification
is especially interesting in areas where there is a high
prevalence of multidrug resistant TB (MDR-TB) and
resistance is associated with specific lineages [2-4]. The
association between lineage type, patient outcome, and
drug resistance needs to be studied to improve future
control measures. Unfortunately the benefits of strain
identification are seldom optimally realized as mycobacter-
ial genotyping, especially lineage identification, is almost
always performed retrospectively on sampled isolates in
high burden settings.
MTB evolves unidirectionally by the accumulation of
mutations that are then fixed with no evidence of genetic
exchange [5,6]. Drug resistance in MTB is almost exclu-
sively conferred via SNPs [7]. Sets of SNPs and LSPs have
also been identified as suitable markers for lineage identifi-
cation within the MTB complex [8-10]. Consequently,
SNP- and LSP-based assays are ideal for combined drug
resistance testing and genotyping of MTB. We have previ-
ously developed and validated a bead-based multiplex
ligation-dependent probe amplification (MLPA) assay and
demonstrated its potential to simultaneously identify a
range of drug resistance markers, discriminate within
the genetic group MTB complex (MTBC), and detect
and identify the clinically most relevant non-tuberculous
mycobacterial species in cultured isolates [10-12].
MLPA assays or MLPA-like assays have been developed
and reported by others for TB [20], other infectious agents
[13-15], human DNA or RNA [16-18]. However, the bead-
based tuberculosis-specific MLPA is unique in having a
multiplexing capacity of up to 50 markers and combined
detection of drug resistance and MTB lineage in a single
assay. For high multiplexing assays a consistency check, i.
e. the presence of sufficient markers and only markers ex-
clusively from a single lineage, and streamlined data inter-
pretation becomes increasingly useful and important as
the numbers of markers screened increases. In previous
reports we made use of a threshold value to classify fluor-
escent signals as positive or negative (see Figure four in,
[10]). This threshold was based on preliminary testing of
DNA from MTBC cultures and allowed accurate identifi-
cation of the presence or absence of targeted markers in
the majority of isolates tested [10]. However for signals
that are close to the threshold automated interpretation of
lineage types and drug resistance profiles can lead to a
small proportion of unidentified false positives/false nega-
tives which are not flagged as low confidence calls. As we
perform a consistency check some of these calls will be
identified, since many TB lineage markers are mutually ex-
clusive, but for drug resistance markers this type of check-
ing is not appropriate as mutations may occur in any
lineage [19] and multiple mutations can be present in dif-
ferent combinations. To overcome this issue different ap-
proaches have been applied; for example adjusting the
threshold value for all markers individually, making use of
the signal-to-noise-ratio [15], reference genes [18], or cal-
culating allelic ratios [20]. Here we have applied intra-
sample normalization and inter-sample correction to allow
low confidence calls to be identified and flagged for scru-
tiny. Identifying intermediate signals allows only the high
confidence calls to be classified as positive and negative.
Automated interpretation for profiles with only high con-
fidence calls can then be trusted without the need to be
reviewed by an expert.
The Republic of Georgia is reported as one of the 18
high-priority countries in the WHO European Region
with the highest TB burden [21]. Additionally in 2011,
15.8% of all diagnosed pulmonary TB patients were re-
ported with at least MDR-TB of which 6.2% were infected
with an extensively resistant TB strain. We collected sam-
ples from patients diagnosed with pulmonary TB at the
National TB Reference Laboratory (NRL) of the National
Center for Tuberculosis and Lung Diseases (NCTBLD) in
Tbilisi, Georgia. In addition to smear microscopy and
chest X-ray, phenotypic drug susceptibility testing (DST)
and molecular drug resistance testing by GenoTy-
peMTBDRplus assay [22-24] is performed routinely in
this setting leading to the continuous reporting of MTB
surveillance data. In contrast there are presently no typ-
ing methods established in this setting and epidemio-
logical data regarding TB lineage type are only assessed
retrospectively outside of the country [25-27].
SNP typing can be complementary to whole genome se-
quencing (WGS) when applied to TB and other pathogens
[9,12,28-30]. Whole genome high throughput sequencing is
probably the ultimate technique for microbial genotyping
but even sequencing a proportion of isolates evolving in a
clonal population structure such as MTB and subsequent
bioinformatic analysis [31] will reveal SNPs uniquely associ-
ated with specific genotypes and will contribute to the
optimization and interpretation of SNP screening assays.
Here, we report a strategy that we have developed to
analyze, visualize and interpret SNP-based data gener-
ated by MLPA while minimizing the required user input.
We assess the degree to which the interpretation of the
results such as resistance profile and MTB lineage can
be confidently assigned.
Results
The principle of the new data analysis method and the
calculation of the correction factors is described in detail
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in the Methods section and in Figure 1. The results ob-
tained with the new data analysis method from DNA of
cultured isolates from individual patient samples collected
at the National TB Reference Laboratory in Tbilisi,
Georgia is illustrated in Figure 2.
After MLPA data normalization, correction and auto-
mated calling, 4238/4300 (98.6%) of the interrogated
markers were classified as positive or negative (Figure 2).
In total 62/4300 (1.4%) markers were classified as inter-
mediate. The 62 intermediate calls were not constraint
to specific strains or specific targeted markers, which
would indicate an underlying structural error in the ana-
lysis (see Additional file 1). In 11 of the 26 strains with
intermediate calls these calls were confined to drug re-
sistance associated markers. The remaining 15 isolates
required expert interpretation for assignment to an
MTB lineage. For 74 of the 100 analyzed isolates a full
MLPA profile was obtained without review by an expert.
The results obtained from the MLPA and from the
reference methods are summarized in Figure 3 and in
Additional file 2. The MLPA produced interpretable
profiles for 99 of the 100 isolates tested using the new
data analysis method (Figure 3). The MLPA genotypes
were called without user interpretation for 74 isolates,
after expert review for a further 25 isolates and one iso-
late produced a profile that was uninterpretable.
To evaluate the accuracy of this calling strategy, all
MLPA results were compared to results obtained from
other methods. We used spoligotypes to validate the
MLPA lineage types and the GenotypeMTBDRplus results
as reference standard to validate the MLPA data obtained
for the markers conferring resistance to first line drugs;
DST was used as reference standard to validate the MLPA
data obtained for the markers conferring resistance to
second line drugs. In addition we have assessed the as-
sociation between drug resistance and MLPA lineage
(see Additional file 3) and MLVA clustering among all
100 isolates (see Additional file 4).
Genotypic lineage identification
The genotypes identified by MLPA and spoligotyping are
compared in Table 1. The MTB4 lineage was the domin-
ant genotype by MLPA (64/99) of which 16 MTB4 isolates
were further classified as Latin American-Mediterranean
(LAM) and eight as Haarlem. Beijing was the second most
commonly identified lineage (35/99), within which the
MLPA identified four sublineages (Table 1). These results
were fully supported by spoligotyping for all but five
isolates (Table 1).
MIRU-VNTR typing data was obtained for 87 samples
of which two isolates (C39 and C67) showed multiple copy
numbers in seven loci (see Additional file 2). Cluster ana-
lysis of the MLVA types revealed 33 isolates with non-
Figure 1 Stepwise approach of the data analysis method. Dot
blots illustrate MFI values for 43 genetic markers targeted in 88
clinical isolates and laboratory strains [10] obtained from (A) the
MAGPIX csv file, (B) after normalization and (C) after normalization
and correction. (A) Raw MFI values obtained for every targeted
marker per strain. The dashed line indicates the threshold of MFI 150
which was initially chosen for the classification of targeted makers.
Red dots show the MFI values obtained which are located in the
intermediate range after normalization and correction in panel C.
(B) MFI values after intra-strain normalization of raw MFI values.
(C) MFI signals after normalization and inter-strain correction using
marker-specific correction factors. The grey area defines the
intermediate range calculated as the area between one and two
standard deviations from the average MFINORM = 860.
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unique MLVA types, forming 10 clusters (see Additional
file 4).
Drug resistance
Results obtained from MLPA were compared to Geno-
TypeMTBDRplus (Table 2) and phenotypic DST results
(see Additional file 5).
Of the 700 loci screened for rifampicin and isoniazid
resistance (katG codon 315, inhA promoter region −15,
rpoB codons 176, 522, 526G and 526 T and 531) by
MLPA in the 100 isolates, 500 could be compared to
data obtained by the GenoTypeMTBDRplus assay (loci
katG codon 315, inhA promoter region −15, rpoB co-
dons 526G and 526 T and 531, the rpoB codons 176 and
522 could not be compared as they are only targeted by
the MLPA assay. Results obtained by MLPA from 463 of
the 500 (92.6%) loci compared were directly supported
by the GenoTypeMTBDRplus assay (Table 2). One iso-
late was identified as isoniazid resistant based on the loss
of the katGWT1 probe by the GenoTypeMTBDRplus
assay (Table 2) and no mutation was identified by MLPA
suggesting the presence of a less common mutation in
katG. For the remaining 37 loci no results were obtained
by the GenoTypeMTBDRplus assay for three isolates (15
loci) and for 14 of the remaining 22 loci intermediate
values were obtained by MLPA. For the remaining eight
(1.6%) loci there was a disagreement between the MLPA
and the GenoTypeMTBDRplus assay.
The rpoB-S531L mutation was the only identified rifam-
picin resistance conferring mutation within the MDR-TB
isolates (Table 2) both by MLPA and GenoTypeMTBDR-
plus. For three MDR isolates no mutation in rpoB was
identified by GenoTypeMTBDRplus or MLPA but the
absence of rpoBWT probes shown by the GenoTy-
peMTBDRplus suggests the presence of a less common
mutation in rpoB (Table 2).
Current probes included in the MLPA for second line
drug testing, target mutations conferring resistance to
the injectable drugs amikacin, kanamycin and capreomy-
cin (rrs1401), capreomycin (rrs1402) or fluoroquinolones
(gyrA90 and gyrA94). MLPA identified resistance to ami-
kacin, kanamycin and capreomycin in two of six MDR-TB
isolates resistant to kanamycin and capreomycin by DST
(see Additional file 5). Two isolates showed resistance to
ofloxacin by DST, but no fluoroquinolone resistance was
detected by MLPA in any of the 100 isolates.
DST identified 16 isolates with ethambutol resistance.
A mutation in the 306 codon of the embB gene confer-
ring resistance to ethambutol was confidently detected
by MLPA in only four isolates all of which were also
phenotypically resistant (see Additional file 5). Addition-
ally MLPA detected an intermediate value for ethambutol
resistance in two isolates one of which was determined
ethambutol resistant by DST (see Additional file 5). MLPA
identified a mutation in the codon 43 of the rpsL gene
conferring resistance to streptomycin in 11 of 52 pheno-
typically streptomycin resistant isolates (25%) and in one
the 44 (2.2%) phenotypically sensitive isolates. In one of
the 52 isolates that were phenotypically streptomycin
resistant an intermediate signal for the rpsl-43 marker
was obtained.
Discussion
We believe that an easily interpretable, robust, high-
throughput multiplex genotyping method such as MLPA
can support infectious disease monitoring and control.
Figure 2 Visualization of data generated from 100 Georgian
isolates after data normalization and data correction. (A) Dot
plot showing normalized and corrected MFI values (black dots) per
isolate for all 4300 markers targeted in the 100 Georgian isolates.
The grey area highlights 62 (1.4%) unclassifiable markers of which 24
are drug resistance markers. Markers located above this area are
classified as positive (971, 22.6%) and below as negative (3267, 76%).
(B) Same data as shown in (A) but only the intermediate values are
shown and visualized per marker. Each line shows the distribution of
normalized and corrected MFI values, sorted from lowest o highest,
(black squares), for one marker (individual colors).
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Critically unlike many typing methods SNP-based geno-
typing is directly compatible with data generated by
WGS/next generation sequencing (NGS). Synergy be-
tween SNP-based surveillance and SNP discovery could
be facilitated by cost-effective high throughput assays.
Moreover, routine screening of clinical isolates with
WGS is currently not feasible in most high prevalence
MDR-TB settings, while a robust and dedicated method
like MLPA is more practical to implement. Also, the
read out platform used here, the Luminex technology is
relatively robust and suitable for other assays notably the
newly developed TB-SPRINT method [32].
As a result of the clonal population structure of the
MTB complex, genotypic information such as SNPs and
large sequence polymorphisms that are not under strong
selective pressure can be used to identify specific geno-
typic lineages and are unique and mutually exclusive. In-
deed, many possible MLPA profiles are invalid, as MTB
is clonal, a pure MTB strain will contain all and only
genetic markers from a single lineage [8,9]. This allows
an internal quality check, unlike classical typing methods
for example IS6110 RFLP typing, or VNTR typing and
to some extent spoligotyping [33-35] where virtually all
profiles are theoretically possible.
Here we have analysed a panel of 100 isolates from pa-
tients diagnosed with pulmonary TB and with positive
sputum smear microscopy collected in 2011 at the
NCTBLD in Tbilisi, Georgia and used the data generated
to evaluate a novel data analysis strategy. From the 100
isolates analyzed, 74 were confidently assigned to an
MTBC lineage by our algorithm without expert inter-
pretation. After expert review of the remaining 26 MLPA
profiles only a single profile remained uninterpretable.
The results of these 99 profiles were compared to refer-
ence methods.
Previously we called positives on the basis of a thresh-
old MFI (equal or higher than 150) with no intermediate
signals [10]. Analyzing the data presented here using the
threshold method would have resulted in 951 of the
4300 characteristics being called positive and 3349 nega-
tive. Using our new data analysis method 971 characteris-
tics were called positive and 3267 called negative, 62 MFI
signals were classified as intermediate. The 62 intermedi-
ate calls were distributed amongst 26 isolates, and 23 of
the 62 (37%) were markers related to drug resistance dis-
tributed amongst 11 isolates. Of these 62 intermediate
calls 13 would have been called positive by the original
analysis method (four correctly, seven incorrectly and two
unknown due to the lack of a reference standard) and 49
negative (21 correctly, 10 incorrectly, 18 unknown). With
respect to lineage identification the threshold method
would have resulted in 22 inconsistent profiles in contrast
to 14 profiles flagged for expert review (of which 13 could
be resolved) with the new data analysis method.
Importantly, as we normalize with pre-established
marker correction factors a single profile can be inter-
preted and no minimum sample size is required to valid-
ate the calls in contrast to other approaches [36]. Those
Figure 3 Results obtained of the 100 isolates by various methods. Samples were taken from 100 individual patients, all diagnosed with
pulmonary TB and producing AFB positive sputum smear; MLPA, DST, GenoTypeMTBDRplus, spoligotyping and MIRU-VNTR was performed on all
100 isolates. DST for first line drugs was performed on all 100 isolates whereas DST for second line drugs was performed on drug-resistant TB
isolates only. DST results were not available for four isolates due to contamination of the respective cultures; No information was obtained from
three isolates tested by GenoTypeMTBDRplus; Spoligotypes were not obtained for one isolate. Unknown spoligotypes were obtained for 17
isolates and the spoligotypes of five isolates were not reported in the SITVITWEB database. MIRU-VNTR types were not obtained for 13 isolates.
Multiple copy numbers in one or more loci were revealed in two isolates; Genotypic information of 45 markers screened per isolate was obtained
for all 100 isolates by MLPA. For 85 isolates, lineage types could be assigned on the basis of consistent lineage marker profiles and in 14 isolates
after expert review. For one isolate the lineage type profile was not interpretable. For 46 isolates molecular drug resistance was identified by
MLPA of which 11 isolates had intermediate signals for at least one drug resistance conferring marker.
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Table 1 Comparison of MLPA lineage types and spoligotypes
Lineage type by spoligotyping
Lineage type by MLPA Beijing H1 H3 LAM1 LAM5 LAM9 T5-RUS1
(LAM)a
T5-RUS1 MANU2 T1 T1-RUS2 T2 T3 T4 T5 Ural-1b Unknown Unknown
(LAM)a
Not reported
before
Not-
interpretable
Beijing K1 (n = 28) 28
Beijing V+/CHIN + (n = 5) 5
Beijing SA-/CHIN- (n = 1) 1
Beijing V- (n = 1) 1
MTB4 other than LAM or
Haarlem (n = 40)
1 1 8 1 1 1 1 9 13 4
LAM (n = 16) 3 1 1 2 3 1 3 1 1
Haarlem (n = 8) 2 6
Non-interpretable (n = 1) 1
Total (100 isolates) 34 2 7 3 1 1 2 3 1 8 1 1 1 1 1 9 17 1 5 1
Lineage types were obtained from spoligotyping using the SITVITWEB database. a, isolates were identified as T5-RUS1 or Unknown according to SITVITWEB but LAM according to their spoligotype identification type
[41]; b, isolates were identified as Ural-1 on the basis of their SIT according to [42]; Numbers in bold indicate disagreement between MLPA and spoligotyping.
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profiles containing of intermediate signals or those with
a profile inconsistent with established lineage identifica-
tion are flagged and need to be inspected by an expert.
This approach means that samples with poor DNA
quality, experimental error or experimental variability
are identified and not spuriously classified automatic-
ally. Figure 2B shows that for each marker, when the
MFI values are ordered from lowest to highest, for the
100 isolates analyzed each marker ideally follows a sig-
moid curve with only very few values in the intermedi-
ate range – these are the intermediate calls.
In the Georgian region a diverse phylogeny of MTB
has been previously observed [25,26,37]. Genotyping by
MIRU-VNTR, spoligotyping and MLPA of 100 randomly
sampled isolates from this region here supports this diver-
sity as well as allowing us to validate our assay by compar-
ing the genotypes obtained by each method. Spoligotypes
were obtained for 99 of the 100 isolates of which 17 were
unknown (ambiguous) in the SITVITWEB database and
five were not previously reported (Table 1). For the 77 iso-
lates for which an MLPA profile and known spoligotype
was available 72 (93.5%) matched. The one isolate with no
MLPA profile available was “direct repeats” negative by
spoligotyping. The 22 isolates with unknown or not previ-
ously reported spoligotypes were all classified to a specific
lineage type by MLPA (Table 1) these classifications were
supported by MIRU-VNTR (see Additional file 2).
Genetic markers under strong selective pressure, most
notably antimicrobial resistance associated mutations,
may occur in multiple lineages [19]. Some lineages have
been suggested to be more associated with (multi-) drug
resistance and therefore identification of some lineages
may be particularly important for public health (reviewed
in [1]). Data collected between 2003 and 2005 in the
WHO European Region and elsewhere shows that major-
ity of MDR-TB isolates belonged to the Beijing lineage [2].
An association of the Beijing lineage with multi-drug
resistance has previously been also observed in Georgia
[25-27] and in the study presented here a member of the
Beijing lineage was 7.4 × (37% versus 5%) more likely to
also have an MDR profile than members from other line-
ages. In order to confirm these findings testing larger
numbers of epidemiologically more representative sample
sets needs to be undertaken. Methods such as MLPA are
suitable to undertake these studies; for example even in
this limited initial study the Beijing clone K1, MLVA type
94–937 was for the first time identified in Georgia for four
isolates two of which were MDR (see Additional file 4).
Intermediate calls might indicate the presence of sen-
sitive and resistant alleles. One isolate that was MDR-TB
by GenotypeMTBDRplus had an intermediate signal for
rpoB-531 and embB306 by MLPA after data analysis,
possibly indicating heteroresistance or mixed infection.
Further evaluation of the data analysis method is required
to prove the ability of the current MLPA to detect hetero-
resistance. The acquisition of resistance during MDR-TB
therapy has also been documented, as was detected by
MLPA, in South Africa and shown to affect the perform-
ance of molecular assays that detect resistance to second
line drugs [38]. Two studies report the occurrence of drug
Table 2 Correlation between drug resistance identified by MLPA and GenoTypeMTBDRplus
Drug resistance by GenoTypeMTBDRplus
Drug resistance by
MLPA
rpoBWT rpoBMUT3 rpoBMUT
othera
katGWT katGMUT1 katGMUT
otherb
inhAWT inhAMUT1 inhAMUT1 and
katGMUT1
No result
no rpoB mutation 76 0 3 2
intermediate rpoB 6 1 0 1
rpoB-S531L (rpoBMUT3) 0 11 0 0
rpoB-S522L 1 0 0 0
no katG mutation 74 0 0 1
katG-S315T (katGMUT1) 0 14 1 1
intermediate katG 1 0 0 0
no inhA mutation 64 0 0 2
inhA-15 C/T (inhAMUT1) 6 2 0 0
inhAMUT1 and katGMUT1 0 0 5 1
intermediate inhA 5 0 0 0
Total isolates
(GenoTypeMTBDRplus)
82 12 3 75 14 1 75 2 5 3
Mutations obtained by MLPA are indicated for the respective genetic marker investigated with the GenoTypeMTBDRplus assay; isolates for which no results were
obtained by GenoTypeMTBDRplus MLPA results for all genetic markers are indicated; an intermediate result indicates the presence of an intermediate signal and
thus no presence or absence for the respective genetic marker; a = two isolates did not show a positive band with the rpoBWT8 probe but no mutation probe
was positive; one isolate did not show a positive band for the rpoBWT3 and rpoBWT4. b = one isolate did not show a positive band with the katGWT1 probe but
no mutation probe was identified.
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resistance amplification and patients infected with more
than one genotype in Georgia [27,39]. Resistance amplifi-
cation and re-infection with MDR-TB isolates could be
partially accountable for the high failure rates in especially
new TB patients in Georgia [21].
At present a limitation of the MLPA assay is that it is
only suitable for use on cultured isolates but developments
in real time assays appear to provide the possibility to per-
form an MLPA assay in a closed tube format [40] which
could dramatically simplify implementation.
Conclusions
At the NCTBLD in Tbilisi, Georgia, no method for exten-
sive genotyping or strain identification was implemented
prior to this work. Therefore, lineage identification and
phylogenetic analysis need to be performed outside of the
NCTBLD. As a result of this study, the development of a
transparent analysis algorithm, and associated staff train-
ing the MLPA method is now able to be performed on site
and a report of the first year’s data is in preparation. Even
when performed locally on cultures, rather than directly
on sputum, combined lineage identification and screening
for drug resistance can provide much needed insight into
the genotypic background of circulating drug resistant
strains in a more timely manner.
Methods
Bacterial/DNA samples
Positive cultures from 100 individual patients referred to
the NRL, Tbilisi, Georgia were collected. Isolates were
randomly selected from patient samples between January
and April 2011 with a positive acid-fast bacilli (AFB)
microscopy result and diagnosed with pulmonary TB;
28 were from patients previously treated for TB. Ethical
approval was not required for this study as no patient
information was used and the results of the analysis of
the bacterial cultures could not be linked back to indi-
vidual patients.
Within the routine workflow for TB patient sample
testing at the NRL the following data was collected:
Sputum samples were directly inoculated onto LJ –based
solid medium and BACTEC MGIT 960 system (BD,
Sparks, MD, USA) drug susceptibility testing (DST)
against first-line drugs for isoniazid and rifampicin was
performed using the absolute proportion method on
Löwenstein-Jensen (LJ) medium or the BACTEC MGIT
960 system [23] and molecular drug resistance testing for
isoniazid and rifampicin using the Genotype MTBDRplus
assay (Hain Lifescience, Nehren, Germany) [22]. Routine
Genotype MTBDRplus assay results were obtained dir-
ectly from DNA extracted from sputum only if the
sputum smear was positive and the sample was no
older than four days, otherwise MTBDRplus was per-
formed on subsequent positive cultures. All isolates
identified as drug-resistant-TB were additionally sub-
jected to second line DST (proportion method on LJ
medium) [23]. DST against the second-line drugs ethi-
onamide (Eto), ofloxacin (Ofx), para-amino-salicylic
acid (PAS), capreomycin (Cm) and kanamycin (Km)
was performed using the proportion method on LJ
medium as previously described [23].
DNA extracted for routine GenoTypeMTBDRplus
testing was also used for MLPA analysis. In brief, 1 ml
bacterial culture was taken from a respective BACTEC
MGIT culture. Bacterial cells were pelleted and resus-
pended in 100 μl molecular grade water. DNA was re-
leased by thermolysis at 95° Celsius for 30 min and
sonication for 15 min. Cell debris was pelleted and the
supernatant containing the DNA was stored at −20°
Celsius. MLPA analysis was performed, as explained
below, without any knowledge of the routine test results
at KIT Biomedical Research (Royal Tropical Institute),
Amsterdam.
MLPA
The bead-based MLPA was performed as previously de-
scribed with an identical 43-plex probe mix [10] on a
MAGPIX® device (Luminex Corp., Austin, Texas, USA).
In brief, 13 drug resistance markers and 30 phylogenetic
informative markers were targeted in the mycobacterial
genome and two controls LumH and LumD were run
with every sample. For quality control of the bead-based
MLPA four control samples are run with every MLPA
experiment [10]: assay control, no template control,
contamination control and MAGPIX control. Molecular
markers associated with resistance to streptomycin (S),
isoniazid (I), rifampicin (R), and ethambutol (E) are in-
cluded targeting respectively the wildtype allele in the
rpsl-43 locus, katG (AGC 315 ACC) and inhA (−15C/T),
rpoB (GTC 176 TTC), rpoB (TCG 522 TTG), rpoB (CAC
526 GAC), rpoB (CAC 526 TAC), rpoB (TCG 531 TTG)
and the wildtype allele in the embB 306 locus. Mutations
associated with molecular resistance to the injectable
drugs amikacin (Am), kanamycin (Km) and capreomy-
cin (Cm) are also targeted by inclusion of probes for the
wildtype allele in rrs (1401) (Am, Km, Cm) and rrs
(1402 C/T) (Cm). The fluoroquinolone (FLQ) resistance
associated mutations gyrA (GCG 90 GTG) and gyrA
(GAC 94 GGC) were also targeted.
The assignment to lineages within the MTB complex
was based on the previously published algorithm [10])
and comprehensive MTB complex phylogeny [8-10]. A
slightly modified version of the algorithm proposed in
[10] was used for the identification of MTB lineages and
sublineages (see Additional file 6). The markers RD-seal
and RD1-mic were added for the identification of Mycobac-
terium microti or Mycobacterium pinnepedii, respectively
and the algorithm for identification of non-tuberculous
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mycobacteria was removed. Raw MFI signals obtained for
all samples from the MAGPIX csv-file are compiled in
Additional file 7.
MLPA data analysis
The csv-file produced after every experiment by the
Luminex xPonent 4.2 software was imported into an
Excel worksheet (Microsoft, Redmond, USA). First an
intra-sample normalization (1. below) on the raw Me-
dian Fluorescence Intensity (MFI) signals was performed
to allow inter-sample comparisons. This was followed by
the application of marker-specific correction factors (2.
below), which simplifies interpretation and visualization
of the results. The MFI signals from the controls LumD
and LumH were excluded from the data normalization
process.
1. Calculation of MFINORM.
On the basis of the currently used MLPA probes and
an optimally performing MLPA assay, at least five
markers will give a true positive signal in every MTB iso-
late with a good quality DNA independent of the drug re-
sistance profile or lineage type. The normalized MFI value
(MFINORM) represents the raw MFI signal (Figure 1A) of
each probe per sample of a run multiplied by an arbitrary
factor (5000) and divided by the sum of the first five
highest MFI signals per isolate (Figure 1B). The value of
5000 as numerator was chosen to facilitate visualization of
the data only. It does not qualitatively influence the data
results.
MFINorm ¼ MFIRAW x 5000sum first five highest MFI signals per isolate
2. Calculation of MFICORR
To ease interpretation and allow a single cut-off to be
applied for each marker all normalized MFI values were
multiplied with previously calculated marker-specific
correction factors.
Calculation of marker-specific correction factors
For the calculation of marker-specific correction factors
previously published data from 88 well characterized la-
boratory strains and clinical isolates [10] were normal-
ized as in (i) above. Then the average MFINORM was
calculated for each marker (e.g. inhA-15) using only the
true positive signals of the marker. The overall average
MFINORM was calculated subsequently by adding all
marker-specific MFINORM averages and dividing by the
number of all markers. The average MFINORM was 850.
We also calculated +1 and −1 standard deviation (SD) of
the average MFINORM (average MFINORM= 850, 1
st SD +/ -
260). The area of low mathematical confidence calls was
determined to be between −1 and −2 SD from the average
of all positives (MFICORR 590 – 330) (Figure 1C, grey area).
Marker-specific correction factors were calculated by divid-
ing the overall average MFINORM (value of 850) with the
marker-specific average MFINORM.
All MFINORM values of a new dataset, here the 100
isolates, were multiplied with the calculated standard
marker-specific correction factors calculated above result-
ing in the corrected MFI (MFICORR) (Figure 2A-B).
Visualization of the raw data with respect to isolate
(Figure 2A) and marker (Figure 2B) is shown. Calling of
the results: For each isolate analyzed the genotype was
called if no intermediate genotypic markers were present
or flagged for final interpretation by an expert if the MFI-
CORR of one or more genotypic markers was in the grey
area (intermediate). Thus genotype profiles were called
without user interpretation, resolved by an expert or iden-
tified as un-interpretable by an expert.
Spoligotyping
Spoligotyping was performed at the University Paris-Sud
on a Luminex 200® and/or on the MAGPIX® platform on
all 100 samples using 43 spacer-spoligotyping [34] on an
aliquot of the same DNA sample used for the MLPA
analysis. Spoligo International Type (SIT) numbers and
lineages were assigned according to the SITVITWEB
database [33] and adapted according to [41,42]. Octal
and binary codes reported in the SITVITWEB database
that do not provide lineage information are referred to
as ‘unknown’. Octal and binary codes that are not identi-
fied in the SITVITWEB database are referred to as ‘not
reported before’.
MIRU-VNTR typing
Standard VNTR typing using 24 loci was performed as
previously described by Supply et al. [43] and optimized
by the RIVM [44] at the RIVM in Bilthoven. Identifica-
tion of MLVA 15–9 codes was carried out by using the
MIRU-VNTRplus database [45]. A cluster was defined
as a minimum of two isolates with identical MIRU-VNTR
patterns.
Statistics
A One-tailed Fisher’s exact test was used to statistically
assess if the MDR phenotype was equally distributed
amongst the genotypes Beijing and non-Beijing. The
P-value was calculated using a two-by-two table with
Beijing and MDR (13 isolates), Beijing and non-MDR
(21 isolates), non-Beijing and MDR (3 isolates), non-
Beijing and non-MDR (58 isolates).
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Additional files
Additional file 1: Table S1. Intermediate calls stratified per individual
marker.
Additional file 2: Table S2. Summary of data obtained for 100 isolates.
Additional file 3: Table S3. DST results for 100 Georgian isolates
stratified according to the MLPA lineage type.
Additional file 4: Table S4. MLVA clusters identified in 100 Georgian
isolates.
Additional file 5: Table S5. Correlation between drug resistance
identified by MLPA and DST.
Additional file 6: Algorithm applied to all isolates analyzed for
lineage identification of Mycobacterium tuberculosis complex. MLPA
markers are framed and final MTB complex lineages or sublineages are
shown in bold. The species identification of a sample starts with the MTB
complex 16SrRNA marker. As an example the call for the Beijing lineage
K1 is highlighted with bold arrows. The following markers are present or
absent in an isolate belonging to the Beijing K1 lineage: MTBC 16S rRNA
(present), TbD1 (present), RD750 (RD sequence present), pks15/1–7
(absent), RD105 (RD sequence deleted), fbpB-238 (present), mutT2-58
(present), acs-1551 (absent), RD131 (RD sequence deleted). MTBC, MTB
complex. EAI, East African Indian; CAS, Central Asian; LAM, Latin American
Mediterranean; Updated version of [10].
Additional file 7: Table S7. Raw MFI data of the MLPA assay.
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